Peril beyond the winner's curse—A small sample size is the bane of biomarker discovery

Peril beyond the winner's curse—A small sample size is the bane of biomarker discovery:

Dementia Big
We thank Mapstone et al. for their comments on our failure to replicate their index findings on plasma metabolite biomarkers of incident Alzheimer disease (AD) [1]. They raise three main concerns with our study [2] which they suggest precludes comparison with their earlier report. We respond to each of these in the following sections:

http://ift.tt/2jOfHMG